- Adeno-associated Virus Vector
- Lentiviral Vector
- Herpes Virus Vector
- Others
Gene Therapy Market was valued at USD 8.9 billion in 2023 and is poised to grow at a CAGR of 21.6% over 2024-2030. A gene is a functioning hereditary unit of life that contains instructions for performing a certain function. Gene therapy is the advanced treatment for cancer, chronic disease, infectious disease, and blood diseases. On the basis of vector type, the Adeno-associated Virus Vector segment is anticipated to hold the major market value in the forecasting market because the Adeno-associated virus (AAV) is a non-enveloped virus that may be modified to transfer DNA to target cells. It has attracted a lot of interest recently, especially in clinical-stage experimental therapy techniques. One of the safest gene therapy technologies so far has been the capacity to manufacture recombinant AAV particles devoid of viral genes and DNA sequences of interest for diverse therapeutic purposes. Adeno-associated Virus vectors are used more frequently than other traditional methodologies due to their ease of use. Considering these benefits, the adeno-associated virus segment is anticipated to grow in the forecasting period. Globally, growth in the prevalence of chronic diseases such as cancer, rare genetic disorders, and others is driving the gene therapy market growth. Moreover, increased government funding, ethical acceptability of gene therapy for cancer treatment, and favorable reimbursement policies contribute to the global gene therapy market growth in the future.
Gene Therapy Market Key Developments:
- In September 2020, Takeda published the results of a Phase II study of TAK-620 (maribavir) for cytomegalovirus (CMV). The drug is designed to target a specific CMV protein, which may lead to inhibition of CMV DNA replication and encapsulation.
- In 2020, Etranacogene dezaparvovec is UniQure’s lead gene therapy candidate and includes an AAV serotype 5 (together “AAV-5”) vector incorporating the functional human Factor IX (“FIX”) Padua variant, conducting a pivotal study in patients with severe and moderately severe hemophilia B
Gene Therapy Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
21.6%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Gene Therapy Market Dynamics
Increase in the R&D expenditure for the development of novel therapeutics has a substantial impact on the global gene therapy market. Market players are aiming to develop a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, potential licensing, merger, and acquisition activities. For instance, In March 2021, Elevate Bio, one of the leading biotech companies focused on gene-based therapies, raised USD 525 million to advance its cell and gene therapy technologies.
North-America Got Significant Share of
Gene Therapy Market Regional Analysis
The gene therapy market in North America accounted to have a significant share in the global gene therapy market followed by europe and the market is expected to grow at a significant cagr over the forecast years due to rising incidence of chronic illnesses, grow in healthcare expenditures, sophisticated healthcare infrastructure, reimbursement availability, and the presence of prominent market players in the area are all propelling the gene therapy market in north america forward.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The gene therapy market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Gene Therapy Market Segmentation
By Vector Type
By Disease Type
- Oncological Disorders
- Neurological Disorders
- Rare Diseases
- Other
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The Gene Therapy Market size was valued at USD 8.9 billion in 2023
Amgen Inc., Bristol-Myers Squibb., Orchard Therapeutics, Gilead Sciences, Novartis AG
Asia-Pacific is the fastest-growing region for Gene Therapy Market
| 1. Executive Summary |
| 2. Global Gene Therapy Market Introduction |
| 2.1. Global Gene Therapy Market – Taxonomy |
| 2.2. Global Gene Therapy Market –Definitions |
| 2.2.1. By Vector Type |
| 2.2.2. By Disease Type |
| 2.2.3. By Region |
| 3. Global Gene Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Current Trends |
| 3.5. Global Gene Therapy Market Dynamic Factors - Impact Analysis |
| 3.6. Mergers, Acquisitions, and Collaborations |
| 4. Global Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Gene Therapy Market, By Vector Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Adeno Virus Vector |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Adeno-associated Virus Vector |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Lentiviral Vector |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Retroviral Vector |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Herpes Virus Vector |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Gene Therapy Market, By Disease Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Oncological Disorders |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cardiovascular Diseases |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Lentiviral Vector |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Retroviral Vector |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Herpes Virus Vector |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Gene Therapy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. MEA |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Region, 2024 - 2030 |
| 8. North America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Adeno Virus Vector |
| 8.1.2. Adeno-associated Virus Vector |
| 8.1.3. Lentiviral Vector |
| 8.1.4. Retroviral Vector |
| 8.1.5. Herpes Virus Vector |
| 8.1.6. Others |
| 8.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Oncological Disorders |
| 8.2.2. Cardiovascular Diseases |
| 8.2.3. Neurological Disorders |
| 8.2.4. Infectious disease |
| 8.2.5. Rare Diseases |
| 8.2.6. Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. United States |
| 8.3.2. Canada |
| 8.4. North America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
| 8.5. North America Gene Therapy Market Dynamics – Trends |
| 9. Europe Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Adeno Virus Vector |
| 9.1.2. Adeno-associated Virus Vector |
| 9.1.3. Lentiviral Vector |
| 9.1.4. Retroviral Vector |
| 9.1.5. Herpes Virus Vector |
| 9.1.6. Others |
| 9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Oncological Disorders |
| 9.2.2. Cardiovascular Diseases |
| 9.2.3. Neurological Disorders |
| 9.2.4. Infectious disease |
| 9.2.5. Rare Diseases |
| 9.2.6. Others |
| 9.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. UK |
| 9.3.2. Germany |
| 9.3.3. France |
| 9.3.4. Italy |
| 9.3.5. Spain |
| 9.3.6. Rest of Europe |
| 9.4. Europe Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
| 9.5. Europe Gene Therapy Market Dynamics – Trends |
| 10. Asia Pacific Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Adeno Virus Vector |
| 10.1.2. Adeno-associated Virus Vector |
| 10.1.3. Lentiviral Vector |
| 10.1.4. Retroviral Vector |
| 10.1.5. Herpes Virus Vector |
| 10.1.6. Others |
| 10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Oncological Disorders |
| 10.2.2. Cardiovascular Diseases |
| 10.2.3. Neurological Disorders |
| 10.2.4. Infectious disease |
| 10.2.5. Rare Diseases |
| 10.2.6. Others |
| 10.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. ANZ |
| 10.3.4. Japan |
| 10.3.5. Rest of APAC |
| 10.4. Asia Pacific Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
| 10.5. Asia Pacific Gene Therapy Market Dynamics – Trends |
| 11. Latin America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Adeno Virus Vector |
| 11.1.2. Adeno-associated Virus Vector |
| 11.1.3. Lentiviral Vector |
| 11.1.4. Retroviral Vector |
| 11.1.5. Herpes Virus Vector |
| 11.1.6. Others |
| 11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Oncological Disorders |
| 11.2.2. Cardiovascular Diseases |
| 11.2.3. Neurological Disorders |
| 11.2.4. Infectious disease |
| 11.2.5. Rare Diseases |
| 11.2.6. Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of LA |
| 11.4. Latin America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
| 11.5. Latin America Gene Therapy Market Dynamics – Trends |
| 12. MEA Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Adeno Virus Vector |
| 12.1.2. Adeno-associated Virus Vector |
| 12.1.3. Lentiviral Vector |
| 12.1.4. Retroviral Vector |
| 12.1.5. Herpes Virus Vector |
| 12.1.6. Others |
| 12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Oncological Disorders |
| 12.2.2. Cardiovascular Diseases |
| 12.2.3. Neurological Disorders |
| 12.2.4. Infectious disease |
| 12.2.5. Rare Diseases |
| 12.2.6. Others |
| 12.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. GCC Countries |
| 12.3.2. South Africa |
| 12.3.3. Rest of MEA |
| 12.4. MEA Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
| 12.5. MEA Gene Therapy Market Dynamics – Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Bristol-Myers Squibb Company |
| 13.2.2. Sanofi SA |
| 13.2.3. F. Hoffmann-La Roche Ltd. |
| 13.2.4. Novartis AG |
| 13.2.5. Shire Plc |
| 13.2.6. Gilead Lifesciences, Inc. |
| 13.2.7. REGENXBIO Inc. |
| 13.2.8. Amgen, Inc. |
| 13.2.9. Celgene Corporation |
| 13.2.10. UniQure N.V. |
| 13.2.11. Orchard Therapeutics Plc |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Bristol-Myers Squibb Company
- Sanofi SA
- Hoffmann-La Roche Ltd.
- Novartis AG
- Shire Plc
- Gilead Lifesciences, Inc.
- REGENXBIO Inc.
- Amgen, Inc.
- Celgene Corporation
- UniQure N.V.
- Orchard Therapeutics Plc